Theranostic Application of FAPI in Advanced Laryngeal Squamous Cell Carcinoma: 99m Tc-FAPI-46 SPECT/CT Guided 177...

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Advanced laryngeal squamous cell carcinoma (LSCC) presents significant treatment challenges, often with metastatic spread.
• Chemotherapy may be insufficient for controlling widespread skeletal metastases in advanced LSCC.
• Accurate staging and monitoring of disease burden are crucial for effective patient management.

Purpose of the Study:

• To evaluate the utility of 99mTc-FAPI-46 SPECT/CT for staging advanced LSCC with skeletal metastases.
• To assess the theranostic potential of 177Lu-FAPI-2286 radioligand therapy in a patient with advanced LSCC and metastatic disease.

Main Methods:

• A patient with advanced LSCC and skeletal metastases underwent 99mTc-FAPI-46 SPECT/CT imaging.
• The patient received 177Lu-FAPI-2286 radioligand therapy as part of a clinical trial for palliative management.
• Post-treatment imaging was performed to assess tracer accumulation.

Main Results:

• 99mTc-FAPI-46 SPECT/CT accurately identified the primary laryngeal tumor, cervical involvement, and extensive skeletal metastases.
• FAPI uptake correlated with known disease sites, reflecting the overall tumor burden.
• Post-therapy imaging confirmed 177Lu-FAPI-2286 accumulation in all disease sites.

Conclusions:

• FAPI-based imaging is a valuable tool for staging and monitoring advanced laryngeal carcinoma.
• FAPI-based radioligand therapy demonstrates theranostic potential for managing metastatic LSCC.
• This approach may improve palliative care and treatment outcomes for patients with advanced laryngeal cancer.